You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 鉅子生物漲超6%再創新高 市值近400億港元 機構唱好
格隆匯 01-16 10:14
格隆匯1月16日丨“膠原蛋白第一股”鉅子生物(2367.HK)再度拉昇漲超6%,盤中高見39.8港元再度刷新上市新高價,總市值近400億港元。上海證券首予鉅子生物“買入”評級,指其高成長高盈利兼具。該行指,膠原蛋白終端應用與需求廣闊,行業保持較快增速。伴隨重組膠原蛋白技術升級、規模化效應及消費者消費認識提升,未來膠原蛋白在功效性護膚、醫用敷料、醫美針劑等多重應用場景上滲透率有望加速提升。公司作為國內重組膠原蛋白龍頭企業,未來有望不斷鞏固行業地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account